Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 26;219(3):e20211057. doi: 10.1084/jem.20211057

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Denali Therapeutics

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 5. — ETV:IDS is more effective than IgG:IDS at reducing brain and CSF GAGs in Ids KO;TfR^mu/hu KI mice. (A–C) GAG levels were evaluated in the liver (A), CSF (B), and brain (C) of Ids KO;TfR^mu/hu KI mice 7 d after treatment with ETV:IDS or IgG:IDS after an IV dose of 1, 3, or 10 mg/kg and compared with vehicle treatment and nondiseased littermate control TfR^mu/hu KI mice. All mice are on a C57BL/6 background. Data presented are from a single study with n = 5 mice per group. Each symbol represents a biological replicate. Graphs display mean ± SEM and P values: one-way ANOVA with Tukey’s multiple comparison test; *, P ≤ 0.05; ***, P ≤ 0.001; ****, P ≤ 0.0001.